Interleukin inhibitors remain a strong growth driver in dermatology
Pharmaceutical Technology
JANUARY 20, 2025
If the results from the clinical development plans are positive, it may well reflect a paradigm shift for clinical care.
Regulator and Funder? FDA’s Orphan Products Grants Program awards significant funding to help move promising treatments through clinical development
FDA Law Blog
NOVEMBER 10, 2024
The Clinical Trials Grants Program provides funding for clinical trials that evaluate the safety and efficacy of potential treatments for rare diseases to help move promising treatments through clinical development. Relative to other areas of medicine (e.g.,
Production 
69
69 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
KFA-115 by Novartis for Melanoma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
KFA-115 is under clinical development by Novartis and currently in Phase I for Melanoma. Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.
LEO Pharma and ICON plc collaborate to improve outcomes for dermatology patients
Outsourcing Pharma
MARCH 14, 2023
A strategic partnership between LEO Pharma and ICON plc, a clinical development company, was announced on March 10.
Dermatology 52
52 
KFA-115 by Novartis for Malignant Mesothelioma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
KFA-115 is under clinical development by Novartis and currently in Phase I for Malignant Mesothelioma. Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.
Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata
The Pharma Data
OCTOBER 29, 2020
30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. vice president of immunology development at Lilly.
Dermatology 52
52 
Use of medical imaging in clinical trials expanding
Outsourcing Pharma
FEBRUARY 2, 2021
While the technology has been found mostly in dermatological applications, its use in studies is expanding, according to Illingworth Research Group.
Iptacopan hydrochloride by Novartis for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Paroxysmal Nocturnal Hemoglobinuria. Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.
Iptacopan hydrochloride by Novartis for Glomerulonephritis: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Glomerulonephritis. Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.
(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Genital Warts (Condylomata Acuminata): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 24, 2023
(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). According to GlobalData, Phase I drugs for Genital Warts (Condylomata Acuminata) have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.
(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Cervical Intraepithelial Neoplasia (CIN): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 24, 2023
(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). According to GlobalData, Phase I drugs for Cervical Intraepithelial Neoplasia (CIN) have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.
Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases
The Pharma Data
OCTOBER 1, 2021
The research, which spans clinical, health economics and outcomes research, translational, clinical pharmacology and preclinical presentations, highlights the breadth and depth of the company’s data on deucravacitinib, a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor, also because the emerging dermatology pipeline.
Dermatology 52
52 
Leqselvi Can Achieve Nearly 90% Scalp Hair Coverage in Severe Alopecia Areata Patients
XTalks
JULY 31, 2024
“An oral JAK that delivers proven results will be impactful for the alopecia areata community,” added Dr. Natasha Mesinkovska, associate professor and vice chair for Clinical Research of Dermatology, University of California, Irvine and investigator in the Leqselvi clinical development program.
Immune Response 105
105 
Sanofi wagers $400m on miRecule muscular dystrophy therapy
pharmaphorum
OCTOBER 5, 2022
There’s little detail on the focus of the alliance, although TrialSpark’s main focus is on rheumatology, dermatology, central nervous system, and cardiometabolic diseases. The aim will be to identify promising candidates in areas of “unmet patient need.”
RNA 105
105 
Risk adjusted net present value: What is the current valuation of Novartis’s Gevokizumab?
Pharmaceutical Technology
FEBRUARY 18, 2023
The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Gevokizumab Overview Gevokizumab (XOMA-052) is developing gevokizumab for the treatment of metastatic colorectal cancer gastroesophageal cancer and colon cancer.
Scepticism in press over Kintor’s COVID-19 US drug trial
pharmaphorum
MAY 14, 2021
China’s Kintor Pharmaceutical has begun late-stage US clinical development of its potential COVID drug proxalutamide – but there is scepticism over the company’s claims about its research. But one of the study’s authors, Brown University dermatology professor Carlos Wambler, dismissed critics and called findings “very encouraging”.
Drug Trials 52
52 
Skin Cancer Awareness Month 2024 and Insights from Medicus Pharma
XTalks
MAY 23, 2024
Companies specializing in dermatology and skincare have developed a range of products aimed at protecting the skin from harmful UV rays. These include broad-spectrum sunscreens, protective clothing and innovative skincare products developed using antioxidants and other protective agents.
Life Science 72
72 
Pfizer Completes Acquisition of Arena Pharmaceuticals
The Pharma Data
MARCH 13, 2022
(NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.
Dermatology 52
52 
Up to 73% of Atopic Dermatitis Patients Taking Lilly’s Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis
The Pharma Data
MAY 1, 2023
Associate Clinical Professor of Dermatology at the University of California San Francisco (UCSF), Director of Medical Dermatology Consultative Services and Patch Testing for the Palo Alto Foundation Medical Group and lead author on the face and hand analysis.
Dermatology 40
40 
Gianluca Pirozzi, MD, PhD, Celebrated for Dedication to the Field of Immunology and Rare Disease Research
The Pharma Data
DECEMBER 10, 2020
Spending several years with Sanofi in Paris, France as a Global safety officer, he then relocated to New Jersey, USA to work in Early and Late Stage Clinical Development in Immunology, when he became the Global Project Head of Dupixent, a medicine that has revolutionized the field of allergic and atopic diseases.
Research 52
52 
Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver
The Pharma Data
MARCH 28, 2022
The focus of the event is on Dupixent ® (dupilumab), a key growth driver, and Sanofi’s rapidly advancing pipeline, highlighting dermatological, respiratory and gastrointestinal diseases as priority therapeutic areas. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement.
Medicine 52
52 
BioSpace Movers & Shakers, Dec. 18
The Pharma Data
DECEMBER 17, 2020
Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group.
Development 52
52 
Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis
The Pharma Data
OCTOBER 9, 2021
Due to the innovative design of deucravacitinib, Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for the science underpinning the clinical development of deucravacitinib.
Trials 52
52 
RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small.
The Pharma Data
AUGUST 19, 2021
Vice President, Clinical Development, Solid Tumors, Janssen Research & Development, LLC. “We Dermatologic Adverse Reactions 7. If skin reactions develop, start topical corticosteroids and topical and/or oral antibiotics. For Grade 3 reactions, add oral steroids and consider dermatologic consultation.
FDA Approval 52
52 
Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track DesignationPhase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month
The Pharma Data
JANUARY 13, 2021
Fast Track designation facilitates the development and expedites the review of drugs that are intended to treat serious and life-threatening conditions and show the potential to fill an unmet medical need. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics.
Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly’s Lebrikizumab Atopic Dermatitis Monotherapy Trials
The Pharma Data
JUNE 7, 2022
These studies are part of the comprehensive clinical development program for lebrikizumab in AD evaluating more than 2,000 patients. Lilly has exclusive rights for development and commercialization of lebrikizumab in the United States and the rest of the world outside Europe. About Lebrikizumab.
Trials 40
40 
Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial
The Pharma Data
MARCH 4, 2021
associate professor of Dermatology at Yale School of Medicine. AA is the second potential treatment indication in dermatology for baricitinib after AD. vice president of immunology development at Lilly. They lose much more than just hair,” said Lotus Mallbris, M.D.,
Trials 52
52 
Rebuilding Clinical Trials in the Image of Patient Need: Key Takeaways from Reuters Pharma Clinical 2021
Pharma Marketing Network
APRIL 30, 2021
Across the board, from rheumatology to neurology, outcomes that matter most to patients, have traditionally not been captured in clinical trials. Charlotte Jones-Burton, MD, VP, Clinical Development, Nephrology, Otsuka. And that should be reflective of the diseases that we’re trying to eradicate.”.
Fixed-dose combination of albuterol and budesonide (PT027) demonstrated significant benefits.
The Pharma Data
SEPTEMBER 9, 2021
It is an inhaled, fixed-dose combination of albuterol (also known as salbutamol), a SABA, and budesonide, a corticosteroid, and is being developed in a pMDI using AstraZeneca’s Aerosphere delivery technology. AstraZeneca and Avillion collaboration.
Trials 52
52 
Bristol Myers Squibb Statement on Opdivo® (nivolumab) Monotherapy Post-Sorafenib Hepatocellular Carcinoma U.S. Indication
The Pharma Data
JULY 23, 2021
Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.
Hormones 52
52 
Bristol Myers Squibb Statement on Opdivo® (nivolumab) Hepatocellular Carcinoma U.S. Indication
The Pharma Data
MARCH 11, 2021
Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.
Trials 52
52 
US companies drive 2023 drug launches positioned for blockbuster success by 2028
Pharmaceutical Technology
MAY 30, 2023
which is the licensee of lebrikizumab, recently reported favourable outcomes for lebrikizumab through a novel secondary analysis of the Phase III clinical development programme. Similarly, Almirall S.A.,
Drugs 264
264 
Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas
The Pharma Data
SEPTEMBER 15, 2020
In addition to the COVID-19 vaccine program, Pfizer aims to deliver five innovative vaccines by 2025, subject to clinical success and regulatory approval. 20vPnC showed a safety and tolerability profile that was similar to Prevnar 13 ® Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]. Inflammation and Immunology.
Gene Therapy 52
52 
CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival
The Pharma Data
AUGUST 11, 2020
Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.
Trials 52
52 
CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers
The Pharma Data
AUGUST 11, 2020
Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.
Trials 52
52 
10 Trends and Statistics for Clinical Trials in 2023
XTalks
MAY 19, 2023
According to the World Health Organization’s (WHO) International Clinical Trials Registry Platform ( ICTRP ), in February 2023, out of 271,906 clinical trials in a known phase of clinical development, 19 percent were in Phase I, 35 percent were in Phase II, 28 percent in Phase III and the remaining 18 percent of trials were in Phase IV.
Almirall demonstrates resilient performance year to date despite COVID-19 impacts
The Pharma Data
NOVEMBER 8, 2020
Ilumetri ® sales grew +125% year-on-year and Seysara ® showed Net Sales performance improvement quarter-on-quarter following clinically relevant FDA label improvement. “Our solid results confirm that we are on the right track to strengthen our leadership position in the medical dermatology space. .
Dermatology 52
52 
Top 7 Pharma Industry Leaders in 2020 By the Numbers
Delveinsight
AUGUST 25, 2021
The Innovative Medicines Division focuses on Oncology, Immunology, Hepatology, Dermatology, Ophthalmology, Neuroscience, Cardiovascular, Renal and Metabolism, and Respiratory. billion followed by the other sectors such as Immunology, Hepatology, and Dermatology (USD 4.86 It generated a revenue of USD 14.71 billion), Respiratory (USD 1.9
Vaccination 98
98 
Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends
XTalks
AUGUST 2, 2023
With Blackstone Life Sciences, up to €300 million (around $315 million USD) will be invested to accelerate pivotal studies and clinical development programs for formulating the subcutaneous delivery of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma. Astellas Pharma Inc.
Sales 98
98 
Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer
The Pharma Data
JANUARY 12, 2021
Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g.
Life Science 52
52 
Saphnelo (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus
The Pharma Data
AUGUST 1, 2021
The approval by the Food and Drug Administration (FDA) was based on efficacy and safety data from the Saphnelo clinical development programme, including two TULIP Phase III trials and the MUSE Phase II trial. 7,8,9,10,11.
Trials 52
52 
Letybo Earns FDA Approval, Hugel Expands Its Global Aesthetic Market Leadership
XTalks
JUNE 17, 2024
RELATED: Innovations and Clinical Trial Diversity in Medical Aesthetics: Insights from Dr. Stephanie Manson Brown, VP & Head of Clinical Development at Allergan Aesthetics – Xtalks Life Science Podcast Ep. 134 How Does Letybo Work?
FDA Approval 52
52 
Crescita Announces Licensing Agreement for Pliaglis; in China
The Pharma Data
NOVEMBER 4, 2020
TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.
Licensing 40
40 
Concert Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Company Update
The Pharma Data
NOVEMBER 4, 2020
Initial data from an ongoing long-term, open label extension study with CTP-543 were presented in the late-breaking news session at the European Academy of Dermatology and Venereology (EADV) Virtual Congress on October 29, 2020. Published Findings on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology.
Let's personalize your content